Bionano Genomics (NASDAQ:BNGO – Get Free Report) and Fortrea (NASDAQ:FTRE – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.
Volatility and Risk
Bionano Genomics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500.
Institutional and Insider Ownership
11.3% of Bionano Genomics shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Bionano Genomics and Fortrea”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bionano Genomics | $28.51 million | 0.56 | -$26.40 million | ($3.02) | -0.38 |
| Fortrea | $2.67 billion | 0.79 | -$986.20 million | ($0.73) | -30.08 |
Bionano Genomics has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Bionano Genomics and Fortrea, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bionano Genomics | 1 | 0 | 1 | 0 | 2.00 |
| Fortrea | 2 | 4 | 6 | 1 | 2.46 |
Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 421.74%. Fortrea has a consensus price target of $23.95, indicating a potential upside of 9.08%. Given Bionano Genomics’ higher possible upside, equities analysts plainly believe Bionano Genomics is more favorable than Fortrea.
Profitability
This table compares Bionano Genomics and Fortrea’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bionano Genomics | -106.58% | -78.78% | -48.54% |
| Fortrea | -2.58% | 13.98% | 2.76% |
Summary
Fortrea beats Bionano Genomics on 11 of the 15 factors compared between the two stocks.
About Bionano Genomics
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
